


# IN THE CLAIMS:

Under 37 C.F.R. § 1.121(c) , please amend the claims as follows:

1.-2. (canceled)

3. (currently amended) A pharmaceutical composition for the treatment of injured mammalian nerve tissue, comprising a pharmaceutically acceptable carrier and an effective amount of a compound ~~of claim 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof.~~ according to the formula:



or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is H or a C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>2</sup> is a  $\text{—}\overset{\text{O}}{\parallel}\text{C—R}^3$  group, a  $\text{—}\overset{\text{O}}{\parallel}\text{P(R}^5\text{)—R}^4$  group or an OR group; wherein R<sup>3</sup> is H, a C<sub>1</sub>-C<sub>20</sub> alkyl group, an OR group, an alkylene ester group

$\text{—(CH}_2\text{)}_n\text{—}\overset{\text{O}}{\parallel}\text{C—OR}^{10}$ , an amine group  $\text{—NR}^{11}\text{R}^{12}$ ; or R<sup>3</sup> and R<sup>6</sup> are taken together to form a  $\text{—(CH}_2\text{)}_m\text{—}$  group where m is 1-3, R is a C<sub>1</sub>-C<sub>20</sub> alkyl group, an aryl group or an alkylene aryl group, R<sup>10</sup> is a C<sub>1</sub>-C<sub>10</sub> alkyl group, n is 1 to 20, R<sup>11</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, aryl, alkylene aryl and an alkylene ester group, and R<sup>12</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, aryl, alkylene aryl and an alkylene ester group; or R<sup>12</sup> and R<sup>6</sup> are taken together to form a  $\text{—(CH}_2\text{)}_z\text{—}$  group where z is 0 to 2, and wherein at least one of R<sup>11</sup> or R<sup>12</sup> is H; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br, I, NO<sub>2</sub> or a NR<sup>13</sup>R<sup>14</sup> group where R<sup>13</sup> and R<sup>14</sup> are H or a C<sub>1</sub>-C<sub>3</sub> alkyl group; or R<sup>14</sup> is taken together with R<sup>3</sup> to form a  $\text{—(CH}_2\text{)}_p\text{—}$  group where p is 0 to 3 ; R<sup>4</sup> and R<sup>5</sup> are aryl or aryloxy; and each of R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br, I and NO<sub>2</sub>.

4. (currently amended) The pharmaceutical composition of claim 3, wherein the compound is selected from the group consisting of:

*N*-(4-Pyridyl) *t*-Butyl Carbamate;  
*N*-(4-Pyridyl) Ethyl Carbamate;  
*N*-(4-Pyridyl) Methyl Carbamate;

*N*-(4-Pyridyl) Isopropyl Carbamate;  
*N*-(4-Pyridyl) Dodecyl Carbamate;  
*N*-(4-Pyridyl) Benzyl Carbamate;  
*N*-(4-Pyridyl) Benzamide;  
*N*-(4-Pyridyl) Acetamide;  
*N*-(4-Pyridyl) Propionamide;  
*N*-(4-Pyridyl) Trimethylacetamide;  
*N*-(4-Pyridyl) Ethyl Succinamate;  
*N, N'*-(4-Pyridyl) Urea;  
*N, N'*-(3,4-Pyridyl) Urea;  
*P, P*-Diphenyl *N*-(4-Pyridyl) Phosphinamide; and  
4-Pyridinyl Phosphoramidic acid, Diphenyl Ester;  
and pharmaceutically acceptable salts, ~~solvates, and polymorphs~~ thereof.

5.-14. (previously canceled)

15.-17. (canceled)